Immunotherapy, Tumor Microenvironment and Survival Signaling
The book is based on the Cancers journal Special Issue entitled "Immunotherapy, Tumor Microenvironment and Survival Signaling", and focuses on important problems concerning tumors and tumor microenvironment interactions, as well as novel immunotherapies such as CAR-T cell therapy. Immunoth...
Saved in:
| Other Authors: | |
|---|---|
| Format: | Electronic Book Chapter |
| Language: | English |
| Published: |
Basel
MDPI - Multidisciplinary Digital Publishing Institute
2022
|
| Subjects: | |
| Online Access: | DOAB: download the publication DOAB: description of the publication |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
MARC
| LEADER | 00000naaaa2200000uu 4500 | ||
|---|---|---|---|
| 001 | doab_20_500_12854_87472 | ||
| 005 | 20220706 | ||
| 003 | oapen | ||
| 006 | m o d | ||
| 007 | cr|mn|---annan | ||
| 008 | 20220706s2022 xx |||||o ||| 0|eng d | ||
| 020 | |a books978-3-0365-4420-5 | ||
| 020 | |a 9783036544199 | ||
| 020 | |a 9783036544205 | ||
| 040 | |a oapen |c oapen | ||
| 024 | 7 | |a 10.3390/books978-3-0365-4420-5 |c doi | |
| 041 | 0 | |a eng | |
| 042 | |a dc | ||
| 072 | 7 | |a M |2 bicssc | |
| 072 | 7 | |a MJ |2 bicssc | |
| 100 | 1 | |a Golubovskaya, Vita |4 edt | |
| 700 | 1 | |a Golubovskaya, Vita |4 oth | |
| 245 | 1 | 0 | |a Immunotherapy, Tumor Microenvironment and Survival Signaling |
| 260 | |a Basel |b MDPI - Multidisciplinary Digital Publishing Institute |c 2022 | ||
| 300 | |a 1 electronic resource (376 p.) | ||
| 336 | |a text |b txt |2 rdacontent | ||
| 337 | |a computer |b c |2 rdamedia | ||
| 338 | |a online resource |b cr |2 rdacarrier | ||
| 506 | 0 | |a Open Access |2 star |f Unrestricted online access | |
| 520 | |a The book is based on the Cancers journal Special Issue entitled "Immunotherapy, Tumor Microenvironment and Survival Signaling", and focuses on important problems concerning tumors and tumor microenvironment interactions, as well as novel immunotherapies such as CAR-T cell therapy. Immunotherapies have recently shown remarkable results in the treatment of cancer patients. However, there are still many questions that remain to be solved in regards to more effective therapies, such as the tumor heterogeneous profile, tumor microenvironment, and tumor survival epigenetic and genetic pathways, all of which make patients resistant to the presently available treatments for cancer. This book demonstrates different approaches to overcome the challenges faced by immunotherapies due to suppressive tumor microenvironments. This book includes 18 papers that can be divided into three chapters: 1. novel immunotherapies; 2. targeting tumor microenvironment and novel approaches; 3. targeting tumors and tumor microenvironment in different types of cancer. | ||
| 540 | |a Creative Commons |f https://creativecommons.org/licenses/by/4.0/ |2 cc |4 https://creativecommons.org/licenses/by/4.0/ | ||
| 546 | |a English | ||
| 650 | 7 | |a Medicine |2 bicssc | |
| 650 | 7 | |a Clinical & internal medicine |2 bicssc | |
| 653 | |a Autophagy | ||
| 653 | |a colorectal cancer | ||
| 653 | |a immunotherapy | ||
| 653 | |a tumor stroma | ||
| 653 | |a tumor microenvironment | ||
| 653 | |a immune checkpoint inhibitors | ||
| 653 | |a chemotherapy | ||
| 653 | |a tyrosine kinase inhibitors | ||
| 653 | |a angiogenesis | ||
| 653 | |a check point inhibitors | ||
| 653 | |a programmed cell death protein 1 | ||
| 653 | |a programmed cell death 1 ligand 1 | ||
| 653 | |a cardiotoxicity | ||
| 653 | |a lung metastasis | ||
| 653 | |a CAR-T | ||
| 653 | |a hypoxia | ||
| 653 | |a tumor | ||
| 653 | |a microenvironment | ||
| 653 | |a CD19 | ||
| 653 | |a BCMA | ||
| 653 | |a cancer | ||
| 653 | |a melanoma | ||
| 653 | |a immune escape | ||
| 653 | |a antigen loss | ||
| 653 | |a chimeric antigen receptor | ||
| 653 | |a electroporation | ||
| 653 | |a lentivirus | ||
| 653 | |a lentiviral transduction | ||
| 653 | |a macrophages | ||
| 653 | |a leukemia cells | ||
| 653 | |a lytic peptides | ||
| 653 | |a targeted therapy | ||
| 653 | |a dendritic cells | ||
| 653 | |a pathogenesis | ||
| 653 | |a risk factors | ||
| 653 | |a breast cancer | ||
| 653 | |a resistance | ||
| 653 | |a checkpoint | ||
| 653 | |a targeted treatment | ||
| 653 | |a personalized medicine | ||
| 653 | |a pediatric solid tumors | ||
| 653 | |a chimeric antigen receptors | ||
| 653 | |a cancer vaccines | ||
| 653 | |a oncolytic viral therapy | ||
| 653 | |a immunomodulation | ||
| 653 | |a DCLK1 | ||
| 653 | |a tumor stem cells | ||
| 653 | |a clonogenicity | ||
| 653 | |a mitochondria | ||
| 653 | |a mitochondrial transfer | ||
| 653 | |a tunneling nanotubes | ||
| 653 | |a triple-negative breast cancer | ||
| 653 | |a immune checkpoint inhibitor | ||
| 653 | |a combination therapy | ||
| 653 | |a cancer nanomedicine | ||
| 653 | |a tumor antigens | ||
| 653 | |a cancer metabolism | ||
| 653 | |a cancer immunotherapy | ||
| 653 | |a nanoparticles | ||
| 653 | |a immunotherapeutic agent | ||
| 653 | |a immunomodulators | ||
| 653 | |a tuft cells | ||
| 653 | |a cancer stem cells | ||
| 653 | |a immunotherapies | ||
| 653 | |a myeloid-derived suppressor cells | ||
| 653 | |a regulatory T cells | ||
| 653 | |a crosstalk | ||
| 653 | |a tumor immune evasion | ||
| 653 | |a cell-cell contact | ||
| 653 | |a β2 integrins | ||
| 653 | |a CD18 | ||
| 653 | |a CD11 | ||
| 653 | |a CAR-T cells | ||
| 653 | |a CD37 | ||
| 653 | |a cell therapy | ||
| 653 | |a tumor antigen | ||
| 653 | |a lymphoma | ||
| 653 | |a CAR macrophage | ||
| 653 | |a CAR T cell | ||
| 653 | |a solid tumors | ||
| 653 | |a immunometabolism | ||
| 653 | |a miRNA | ||
| 653 | |a immunogenic cell death | ||
| 653 | |a n/a | ||
| 856 | 4 | 0 | |a www.oapen.org |u https://mdpi.com/books/pdfview/book/5660 |7 0 |z DOAB: download the publication |
| 856 | 4 | 0 | |a www.oapen.org |u https://directory.doabooks.org/handle/20.500.12854/87472 |7 0 |z DOAB: description of the publication |